somatropin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Foetal Growth Problem

Conditions

Foetal Growth Problem, Small for Gestational Age

Trial Timeline

Nov 1, 2002 → Jul 1, 2006

NCT ID

NCT00184756

About somatropin

somatropin is a phase 3 stage product being developed by Novo Nordisk for Foetal Growth Problem. The current trial status is completed. This product is registered under clinical trial identifier NCT00184756. Target conditions include Foetal Growth Problem, Small for Gestational Age.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03435627	Pre-clinical	Completed	Feb 26, 2018	Jan 18, 2022	Genetic Disorder
NCT01927861	Phase 3	Completed	Aug 19, 2013	Jul 12, 2018	Genetic Disorder
NCT01778023	Phase 3	Completed	Jan 17, 2013	Dec 17, 2014	Growth Disorder
NCT01435629	Pre-clinical	Completed	Nov 22, 2012	Dec 4, 2015	Genetic Disorder
NCT01110928	Pre-clinical	Completed	Nov 26, 2009	Nov 12, 2018	Foetal Growth Problem
NCT01109017	Pre-clinical	Completed	Oct 1, 2009	Dec 1, 2014	Growth Hormone Disorder
NCT00934063	Pre-clinical	Completed	Jul 1, 2009	Jun 1, 2014	Growth Hormone Disorder
NCT00705172	Pre-clinical	Completed	Nov 1, 2008	Nov 1, 2008	Genetic Disorder
NCT00519844	Approved	Completed	Jul 1, 2005	Jan 1, 2006	Foetal Growth Problem
NCT01604161	Pre-clinical	Completed	May 1, 2005	Jun 1, 2015	Growth Hormone Disorder
NCT00184730	Phase 3	Completed	Nov 1, 2004	Sep 1, 2006	Growth Hormone Disorder
NCT00184743	Phase 3	Completed	Dec 6, 2003	Dec 28, 2005	Growth Hormone Disorder
NCT00557336	Phase 3	Completed	Jul 28, 2003	Jun 29, 2005	Foetal Growth Problem
NCT01580605	Pre-clinical	Completed	Jul 17, 2003	Nov 28, 2011	Growth Hormone Disorder
NCT01543880	Pre-clinical	Completed	Jul 1, 2003	Jun 1, 2014	Growth Hormone Disorder
NCT00519558	Phase 3	Completed	May 31, 2003	Jan 24, 2005	Growth Hormone Disorder
NCT00102817	Phase 3	Completed	May 1, 2003	Dec 1, 2006	Growth Hormone Disorder
NCT00184652	Phase 2	Completed	Apr 1, 2003	Sep 1, 2005	Chronic Kidney Disease
NCT00567385	Approved	Completed	Mar 10, 2003	Mar 22, 2004	Growth Hormone Disorder
NCT00184756	Phase 3	Completed	Nov 1, 2002	Jul 1, 2006	Foetal Growth Problem

Competing Products

8 competing products in Foetal Growth Problem

See all competitors

Product	Company	Stage	Hype Score
somatropin + somatropin + somatropin	Novo Nordisk	Approved	84
somatropin	Novo Nordisk	Phase 3	76
somatropin	Novo Nordisk	Phase 3	76
somatropin	Novo Nordisk	Pre-clinical	22
somatropin + somatropin	Novo Nordisk	Phase 3	76
somatropin	Novo Nordisk	Approved	84
somatropin + somatropin	Novo Nordisk	Approved	84
somatropin + No treatment given + No treatment given	Novo Nordisk	Pre-clinical	22

Other Products from Novo Nordisk

Liraglutide 3.0mg + Placebo Oral Tablet + Phentermine 15 MGApproved

Liraglutide + SalineApproved

Hydrocortisone + PlaceboApproved

biphasic insulin aspart + insulin aspartApproved

Semaglutide, 1.34 mg/mL + Empagliflozin 25 MGApproved